TUCSON, Ariz., July 10, 2017 /PRNewswire/ -- COPD
hospitalizations are at an all-time high. The 30-day readmission
rate for patients ranges from 20-39 percent1-3, with
related healthcare costs at an estimated $50
billion4-5. A recently published study, funded by
Royal Philips (NYSE: PHG, AEX: PHIA), revealed that although
positive airway pressure (PAP) therapy was associated with a
reduction in hospitalization, more than 92 percent of patients
studied were not receiving it in any form.
The retrospective study led by Dr. Sairam Parthasarathy, professor of medicine and
interim chief of Division of Pulmonary, Allergy, Critical Care and
Sleep Medicine with University of
Arizona College of Medicine, revealed that only 7.5 percent
of the more than 1.8 million COPD patients analyzed were receiving
any form of PAP therapy. There are multiple modes of PAP treatment
which can take place at home to help people alleviate symptoms of
respiratory illness. The reviewed administrative claims data
suggested that individuals receiving either Bi-level (BiPAP),
continuous (CPAP) or noninvasive positive pressure ventilation
(NIV) therapy (n=48,856) experienced lower hospitalization risk
than before therapy initiation as well as lower hospitalization
risk than those who did not receive any positive airway pressure
therapy at all.
"Frequent readmissions of COPD patients not only disrupt their
quality of life, but are costing our health systems billions," says
Parthasarathy. "This analysis revealed that there is a
solution already accessible within our toolbox that can keep
patients out of the hospital, but it is significantly
underutilized. With improved awareness and implementation of PAP
therapy as a treatment for COPD, we can lower the cost burden for
health systems while allowing patients to recover in the comfort of
their own homes."
"Many clinicians still reference dated information when
considering COPD treatment methods, yet technologies, machines and
even masks have advanced significantly since PAP therapy was first
introduced," says Eli Diacopoulos,
Philips Respiratory Care Business Leader. "This study demonstrates
the vast opportunity for the industry to further adopt recent
innovations for COPD treatment."
Patients with multiple chronic medical conditions were analyzed
as part of this bioinformatics "real world" study. Comorbidities
such as sleep apnea, chronic respiratory failure and heart failure
were associated with greater benefits from PAP therapy, though
ultimately, results showed that further clinical study into a
causal connection between PAP therapy and reduced hospital
readmissions of COPD patients is warranted.
As part of its continued commitment to pioneering the
development of hospital-to-home solutions designed to help people
breathe easier, Philips has recently sponsored two additional
studies related to COPD patient hospitalization. The first found
the use of advanced home non-invasive ventilation (NIV),
specifically Trilogy with AVAPS-AE, to significantly decrease
hospital and payer costs as well as hospitalization rates for
patients with severe COPD. Another suggested that NIV paired with
home oxygen therapy can prolong the length of admission-free
survival.
Philips offers a wide variety of PAP therapy solutions for COPD
patients, including DreamStation Advanced Therapies and its Trilogy
line of hospital-to-home ventilators, each connected to the Care
Orchestrator patient management application. For additional
information on Philips' PAP offerings and additional solutions for
sleep and respiratory care, follow @PhilipsResp or visit
www.respironics.com.
For further information, please contact:
Meredith Amoroso
Philips Sleep and Respiratory Care
Mobile: +1 724-584-8991
E-mail: meredith.amoroso@philips.com
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient monitoring and
health informatics, as well as in consumer health and home care.
Philips' health technology portfolio generated 2016 sales of
EUR 17.4 billion and employs
approximately 70,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.com/newscenter.
View original
content:http://www.prnewswire.com/news-releases/philips-sponsored-study-suggests-positive-airway-pressure-therapy-could-reduce-copd-patient-hospitalization-300484953.html
SOURCE Royal Philips